Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.70 |
| ▸ | TK2 | O00142 | 4/20 | 0.65 |
| ▸ | TYMP | P19971 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | ALB | P02768 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.60 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.60 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.60 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2786143 | 1.00 | PYGM (0.70) | PYGMTK2TYMPALDH1A1LMNA | |
| SCHEMBL10812613 | 1.00 | PYGM (0.70) | PYGMTK2TYMPALDH1A1LMNA | |
| SCHEMBL12103839 | 1.00 | PYGM (0.70) | PYGMTK2TYMPALDH1A1LMNA | |
| SCHEMBL453142 | 1.00 | PYGM (0.70) | PYGMTK2TYMPALDH1A1LMNA | |
| SCHEMBL14388592 | 1.00 | PYGM (0.70) | PYGMTK2TYMPALDH1A1LMNA | |
| SCHEMBL22143517 | 1.00 | PYGM (0.70) | PYGMTK2TYMPALDH1A1LMNA | |
| SCHEMBL1983444 | 1.00 | PYGM (0.70) | PYGMTK2TYMPALDH1A1LMNA | |
| SCHEMBL10340724 | 1.00 | PYGM (0.70) | PYGMTK2TYMPALDH1A1LMNA | |
| SCHEMBL10815567 | 1.00 | PYGM (0.70) | PYGMTK2TYMPALDH1A1LMNA | |
| SCHEMBL29299 | 1.00 | PYGM (0.70) | PYGMTK2TYMPALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-1009995-A | — | — | None | — | — | JP | disclosed |
| US-10100076-B2 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | GILEAD PHARMASSET LLC (US) | 2018-10-16 | — | — | US | disclosed |
| US-20140057863-A1 | MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | GILEAD SCIENCES, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20110269707-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation | PHARMASSET, INC. | 2011-11-03 | — | — | US | disclosed |
| EP-1411954-B1 | MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | PHARMASSET INC (US) | 2010-12-15 | — | — | EP | disclosed |
| EP-2251015-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | Pharmasset, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| EP-2157095-A2 | Synthesis of beta-L-2-Deoxy nucleosides | Novartis Ag (CH) | 2010-02-24 | — | — | EP | disclosed |
| EP-1639121-A4 | SYNTHESIS OF BETA -L-2-DEOXY NUCLEOSIDES | IDENIX CAYMAN LTD (KY) | 2008-04-16 | — | — | EP | disclosed |
| EP-1639121-A2 | SYNTHESIS OF BETA -L-2-DEOXY NUCLEOSIDES | Idenix (Cayman) Limited (KY) | 2006-03-29 | — | — | EP | disclosed |
| US-20050059632-A1 | Synthesis of beta-L-2'-deoxy nucleosides | NOVARTIS AG (CH) | 2005-03-17 | — | — | US | disclosed |
| EP-0292101-A3 | PROCESS FOR THE PREPARATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE AND INTERMEDIATES | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-01-31 | — | — | EP | disclosed |
| EP-0295090-A3 | CHEMICAL PROCESS | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-01-31 | — | — | EP | disclosed |
| EP-0301908-A2 | 1-(3,5-Di-0-benzoyl-2-deoxy-beta-D-threo-pentofuranosyl)thymine and the method of producing the same | Ceskoslovenska akademie ved (CS) | 1989-02-01 | — | — | EP | disclosed |
| EP-0295090-A2 | Chemical process | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-12-14 | — | — | EP | disclosed |
| EP-0295090-A2 | Chemical process | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-12-14 | — | — | EP | disclosed |
| EP-0292101-A2 | Process for the preparation of 3'-azido-3'-deoxythymidine and intermediates | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-11-23 | — | — | EP | disclosed |
| EP-0292101-A2 | Process for the preparation of 3'-azido-3'-deoxythymidine and intermediates | THE WELLCOME FOUNDATION LIMITED (GB) | 1988-11-23 | — | — | EP | disclosed |
| US-4659698-A | Pharmaceutical compositions based on xylosides and lyxosides of purine and pyrimidine bases used in a method of treating viruses | SYNTHELABO (FR) | 1987-04-21 | — | — | US | disclosed |
| US-4659698-A | Pharmaceutical compositions based on xylosides and lyxosides of purine and pyrimidine bases used in a method of treating viruses | SYNTHELABO (FR) | 1987-04-21 | — | — | US | disclosed |
| US-4017606-A | CYTOSINE ARABINOSIDE AND HYDROGENATED PYRIMIDINE NUCLEOSIDES | THE UPJOHN COMPANY (US) | 1977-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057863-A1 | MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | SLC29A1, PNP, SLC29A2 | PYGM 89/4885TK2 149/4885TYMP 39/4885 |
| US-20110269707-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation | PNP, ALPP, XDH | PYGM 4/4885TK2 261/4885TYMP 19/4885 |
| US-10100076-B2 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | SLC29A1, SLC29A2, PNP | PYGM 99/4885TK2 159/4885TYMP 33/4885 |
| US-20050059632-A1 | Synthesis of beta-L-2'-deoxy nucleosides | DUT, DERA, RNASEL | PYGM 1166/4885TK2 341/4885TYMP 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.